Phase III migraine flop sends a small-cap biotech player into a deadly tailspin

A small-cap player looking to cash in quickly on a reformulated drug just got flattened this morning as their one-trick pony got hit by a late-stage catastrophe. Bay Area-based Satsuma Pharmaceuticals $STSA made it to the market a year ago with an upsized take of $83 million based on their…

Click to view original post